PLEASANTON, Calif.,
March 31, 2016 /PRNewswire/
-- Each year in the United
States, at least 2 million people become infected with
bacteria that are resistant to antibiotics and at least 23,000
people die as a direct result of these infections.1
According to the U.S. Centers for Disease Control and Prevention
(CDC), antibiotic stewardship – the commitment to use antibiotics
only when necessary to treat or prevent disease –
combined with steps to prevent hospital-associated infections
(HAIs) and transmission of resistant bacteria, is critical to
stopping the spread of antibiotic resistance.2
Experience the interactive Multimedia News Release here:
http://www.multivu.com/players/English/7794251-clorox-healthcare-nasal-antiseptic-swabs/
In 2014, one in seven surgical site infections (SSIs) was caused
by antibiotic-resistant bacteria identified as urgent or serious
threats by the CDC.2 Nasal decolonization has become an
important strategy to reduce the risk of SSIs as part of a bundled
approach to infection prevention. However, growing evidence of
bacterial resistance to commonly used antibiotics and the
consequent potential for decolonization failure has made evaluating
non-antibiotic methods a priority. Reducing unnecessary antibiotic
use can help decrease antibiotic resistance and healthcare costs,
and improve patient outcomes.3
To help healthcare professionals in their ongoing efforts to
protect patients from SSIs, Clorox Healthcare is introducing Clorox
Healthcare™ Nasal Antiseptic Swabs, a povidone-iodine alternative
to antibiotics, at the Association of periOperative Registered
Nurses (AORN) Surgical Conference and Expo.
Using an antiseptic, like Clorox Healthcare™ Nasal Antiseptic
Swabs, instead of an antibiotic, like mupirocin, for preoperative
nasal decolonization is a simple and effective way for any
healthcare facility to reduce unnecessary antibiotic use.
"Clorox Healthcare understands the urgency to act on antibiotic
stewardship," said Dr. Rosie D.
Lyles, Head of Clinical Affairs for Clorox Healthcare.
"Antibiotics save lives, but inappropriate prescribing and misuse
puts patients at risk."
"It was important to us to bring forward an antiseptic nasal
decolonization solution that would help protect patients from SSIs
and antibiotic-resistant bacteria while enabling stewardship. Using
the swabs can also increase the likelihood of compliance because
the responsibility for application is shifted from patients to
trained healthcare professionals."
SSIs are common and costly for both healthcare facilities and
patients. They account for approximately 23 percent of
HAIs4 and an excess of up to $3.5
billion in healthcare expenditures per year.5 The
per-patient cost for an SSI can be as high as $60,0006 and increase the average
length of hospital stays from seven to 11 days.5
Benefits of Clorox Healthcare™ Nasal Antiseptic
Swabs
Clorox Healthcare™ Nasal Antiseptic Swabs offer several key
benefits as part of preoperative and inpatient decolonization
strategies:
- Safe and Efficient Alternative to Antibiotics: Clorox
Healthcare™ Nasal Antiseptic Swabs are clinically shown
to be non-irritating and well tolerated in the nares after 10
applications.7 They are further shown to reduce 99.4% of
S. aureus at 1 hour and maintain persistence through 12
hours in an in vitro study.8
- Simple and Easy to Use:
Clorox Healthcare™ Nasal Antiseptic Swabs are
pre-saturated, ready-to-use swabs that are applied to a patient's
nostrils by a healthcare provider one hour before surgery. This
method shifts the responsibility for nasal decolonization from
patients to trained healthcare professionals, increasing the
likelihood of compliance. Nasal Antiseptic Swabs were determined by
patients to be comfortable during application and reported an
overall positive experience.7
- No Evidence of Bacterial Resistance: There is growing
evidence of resistance of Staphylococcus aureus (S.
aureus) and methicillin-resistant Staphylococcus aureus
(MRSA) to mupirocin. High-level resistance has been associated with
nasal decolonization failure.9 Clorox Healthcare™ Nasal
Antiseptic Swabs contain povidone-iodine, an antiseptic that has
broad activity against gram-positive and gram-negative bacteria.
This antiseptic has been in use for over 50 years and to date,
studies have not shown that bacteria develop resistance to
povidone-iodine.10,11
Bringing Nasal Decolonization to Life at AORN Surgical
Conference and Expo
At the AORN Surgical Conference and
Expo, the largest gathering of perioperative professionals in
the United States, Clorox
Healthcare will bring attention to nasal decolonization as an
important part of plans for SSI prevention and antibiotic
stewardship through an immersive virtual reality experience. Clorox
Healthcare booth (#313) attendees will be able to view a 360° video
that puts them in the shoes of a healthcare provider performing
nasal decolonization in a real-world setting. For those unable to
attend the conference, for an optimal 360° experience, watch the
video from your virtual reality headset or smartphone by visiting
Clorox Healthcare's YouTube channel.
To further help AORN conference attendees understand the issue
of nasal decolonization, Dr. Lyles will lead a continuing education
(CE) presentation at the Clorox Healthcare booth (#313) titled,
"Nasal Decolonization: Alternatives to Antibiotics." The free
CE credit presentation will discuss the causes and clinical and
economic impact of HAIs and SSIs, problems associated with
antibiotic therapy, antiseptic alternatives to antibiotics for
nasal decolonization, and best practices.
For more information, including complimentary educational
resources such as kits, training materials and sample products,
visit www.CloroxHealthcare.com/NasalAntisepticSwabs.
About Clorox Healthcare
Building on a century-long legacy in cleaning and disinfecting,
Clorox Healthcare offers a wide range of products to help stop
the spread of infection in healthcare facilities. From
comprehensive surface disinfection, including advanced ultraviolet
technology, to skin antisepsis, we are committed to providing
efficacious solutions to the healthcare community. For more
information, visit www.CloroxHealthcare.com or follow
@CloroxHealth on Twitter.
NYSE: CLX
CLX-B
1. Antibiotic / Antimicrobial Resistance. U.S.
Department of Health and Human Services, Centers for Disease
Control and Prevention. http://www.cdc.gov/drugresistance/.
Accessed 1/26/2016.
2. Weiner LM, Fridkin SK, Aponte-Torres Z, et al.
Vital Signs: Preventing
Antibiotic-Resistant Infections in Hospitals — United States, 2014. MMWR Morb Mortal Wkly
Rep. ePub: 3 March 2016.
3. Get Smart for Healthcare: Overview and Evidence to
Support Stewardship. U.S. Department of Health and Human Services,
Centers for Disease Control and Prevention.
http://www.cdc.gov/getsmart/healthcare/evidence.html. Accessed
2/4/2016.
4. Sievert DM et al. National Healthcare Safety Network
(NHSN) Team and Participating NHSN Facilities.
Antimicrobial-resistant pathogens associated with
healthcare-associated infections: summary of data reported to the
National Healthcare Safety Network at the Centers for Disease
Control and Prevention, 2009-2010. Infect Control Hosp Epidemiol.
2013 Jan;34(1):1-14.
5. Anderson DJ, Podgorny K, Berrios-Torres SI, et al.
"Strategies to Prevent Surgical Site Infections in Acute Care
Hospitals: 2014 Update." Infection Control and Hospital
Epidemiology 35.6(2014): 605-627.
6. Anderson DJ et al, "Clinical and Financial Outcomes
Due to Methicillin Resistant Staphylococcus
aureus Surgical Site Infection: A Multi-Center Matched
Outcomes Study," PLOS ONE 2009 Dec 15;4(12).
7. The Clorox Services Company Study Number:
2015-002/2015-003
8. In vitro Clorox Technical Services; Clorox Study
#9550-005
9. Hetem DJ, Bonten MJ. Clinical relevance of mupirocin
resistance in Staphylococcus aureus. J Hosp Infect. 2013
Dec;85(4):249-56.
10. Houang ET et al. Absence of bacterial resistance to
povidone iodine. J Clin Pathol. 1976 Aug;29(8):752-5.
11. Lanker Klossner B et al. Nondevelopment of
resistance by bacteria during hospital use of povidone-iodine.
Dermatology. 1997;195 Suppl 2:10-3.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/global-threat-of-growing-antibiotic-resistance-highlights-need-for-antiseptic-alternatives-300243917.html
SOURCE Clorox Healthcare